Abstract: The present invention relates to the treatment of IgE-mediated disease. The inventors hypothesized that formation of immune complexes between Omalizumab and IgE might be responsible for some of the adverse reactions observed in highly atopic patients (i.e. patients with a history of anaphylaxis and/or high IgE titers). Immune complexes can induce inflammation through activation of Fc gamma receptors (Fc?Rs) and/or the complement cascade. They identified that Omalizumab:hIgE immune complexes activate human Fc?Rs in vitro. Moreover, similarly to some of the reported side effects observed in human, Omalizumab:hIgE immune complexes can induce anaphylaxis when injected in mice expressing human Fc?Rs. Using publicly available omalizumab VH and VL sequences, they cloned and produced two mutant versions of omalizumab in which residues in the Fc portion of the Ab were mutated.

Abstract: An immunogenic product including at least one immunoglobulin or fragment thereof conjugated with a carrier protein, wherein the at least one immunoglobulin is IgE and preferably wherein the IgE fragment includes the IgE C?3 domain, and wherein the carrier protein is preferably CRM197. Also the use of this immunogenic product for treating inflammatory disorders, and in particular allergic disorders.

Abstract: The present invention relates to novel antibodies, in particular murine monoclonal antibodies, chimeric and humanized, that are able to block specifically the human IgG receptors Fc?RIIIA (CD16A) and Fc?RIIIB (CD16B) as well as the amino and nucleic acid sequences coding for such antibodies. The invention also comprises the use of such antibodies or of fragments thereof as a medicament for the preventive and/or therapeutic treatment of diseases involving CD16, like autoimmune diseases, inflammatory disorders, allergies and infections, without inducing any adverse effects. In particular, these antibodies and fragments can prevent or treat anti-drug idiopathic thrombocytopenic purpura (ITP), rheumatoid arthritis (RA) and autoimmune hemolytic anemia (ANA).

Abstract: An immunogenic product including a cytokine conjugated with a carrier protein, wherein the cytokine is selected from the group including IL-4, IL-13 and mixtures thereof, and wherein the carrier protein is CRM197. Further, a method for manufacturing the immunogenic product. Also, the therapeutic use of the immunogenic product for treating an inflammatory disorder associated with aberrant IL-4 and/or IL-13 expression or activity.

Abstract: The present invention relates to the treatment of IgE-mediated disease. The inventors hypothesized that formation of immune complexes between Omalizumab and IgE might be responsible for some of the adverse reactions observed in highly atopic patients (i.e. patients with a history of anaphylaxis and/or high IgE titers). Immune complexes can induce inflammation through activation of Fc gamma receptors (Fc?Rs) and/or the complement cascade. They identified that Omalizumab:hIgE immune complexes activate human Fc?Rs in vitro. Moreover, similarly to some of the reported side effects observed in human, Omalizumab: hIgE immune complexes can induce anaphylaxis when injected in mice expressing human Fc?Rs. Using publicly available omalizumab VH and VL sequences, they cloned and produced two mutant versions of omalizumab in which residues in the Fc portion of the Ab were mutated.

Abstract: The present invention relates to the prevention and/or treatment of arthritic, inflammatory and/or allergic reactions as well as thrombocytopenia, by blocking the human receptors FcyRI and FcyRIIA. It is disclosed a mouse monoclonal antibody (mAb) which efficiently blocks human FcyRI and can therefore be used, alone or in a combination product, for example with an anti-hFcyRIIA blocking antibody, in the prevention and/or the treatment of these diseases.

Abstract: Lactobacillus compositions, especially those based on L. casei, and methods for the prevention and treatment of diseases or disorders involving or mediated by mast cells, such as anaphylaxis, allergy, autoimmune and inflammatory disorders including arthritis and rheumatoid arthritis.